表纸
市场调查报告书

逆流性食道炎(胃食道逆流症):开发平台分析

Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品编码 232845
出版日期 内容资讯 英文 87 Pages
订单完成后即时交付
价格
Back to Top
逆流性食道炎(胃食道逆流症):开发平台分析 Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline Review, H1 2019
出版日期: 2019年02月01日内容资讯: 英文 87 Pages
简介

胃液逆流到食道就称之为胃食道逆流症(GERD),症状有恶心、胃灼热、呕吐等。造成下食道括约肌(LES)开关失常的过度饮食、肥胖、怀孕、过油食物、部分医药品都是致病因子。

本报告函括全球逆流性食道炎(胃食道逆流症)治疗药的开发平台,提供您目前开发平台状况和最新趋势,药物简介,主要企业及开发中的产品评估等,为您概述为以下内容。

目录

简介

  • 分析范围

逆流性食道炎(胃食道逆流症)概要

治疗药的开发

  • 逆流性食道炎(胃食道逆流症)开发中产品:概要
  • 逆流性食道炎(胃食道逆流症)开发中产品:比较分析

逆流性食道炎(胃食道逆流症):开发中的治疗药:各企业

逆流性食道炎(胃食道逆流症):开发中的治疗药:大学·研究机关别

逆流性食道炎(胃食道逆流症):开发中产品概况

  • 后期阶段的产品
  • 临床实验阶段的产品
  • 初期阶段的产品

逆流性食道炎(胃食道逆流症):开发中的产品:各企业

逆流性食道炎(胃食道逆流症):开发中的产品:大学·研究机关别

逆流性食道炎(胃食道逆流症):治疗药的开发企业

  • Ahn-Gook Pharmaceutical Co., Ltd.
  • aRigen Pharmaceuticals, Inc.
  • Cempra, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • Eisai
  • Ironwood Pharmaceuticals, Inc.
  • Johnson & Johnson
  • RaQualia Pharma Inc.
  • Shire Plc
  • Sucampo Pharmaceuticals, Inc.
  • Vecta Ltd.
  • Wockhardt Limited
  • Yuhan Corporation
  • Yuyu Pharma, Inc.

逆流性食道炎(胃食道逆流症):治疗药的评估

  • 单剂治疗药
  • 组合产品
  • 标的别
  • 各作用机制
  • 各给药途径
  • 各分子类型

药物简介

  • ARH-1029
  • cobiprostone
  • DWJ-1367
  • E-3710
  • Esomeprazole镁
  • G-17DT
  • IW-3718
  • JNJ-26070109
  • omepurazoru
  • pantopurazoru
  • RQ-00000004
  • RQ-00000774
  • 消化性溃疡治疗药
  • GERD及糖尿病性胃轻瘫细叶冬青磷受体抑制剂
  • 消化器官疾病质子帮浦抑制剂
  • SSP-002358
  • tenatopurazoru
  • YH-4808
  • YY-DXR
    • 产品概要
    • 作用机制
    • R&D的进展

最新的开发平台趋势

暂停中的计划

开发中止的产品

产品开发里程碑

  • 关注的新闻·新闻稿

附录

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11056IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Reflux Esophagitis - Pipeline Review, H1 2019, provides an overview of the Reflux Esophagitis (Gastrointestinal) pipeline landscape.

When the liquid content of the stomach refluxes into the oesophagus, that condition is called Gastro esophageal reflux disease (GERD). It is a chronic condition. The symptoms of GERD are nausea, heartburn and vomiting. The predisposing factors include eating large meals, which can cause the Lower Esophageal Sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food and certain drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Reflux Esophagitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Reflux Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Reflux Esophagitis (Gastro esophageal Reflux Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 6, 6, 4, 1 and 1 respectively.

Reflux Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Reflux Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Reflux Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Reflux Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Reflux Esophagitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Overview
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Companies Involved in Therapeutics Development
    • Ahn-Gook Pharmaceutical Co Ltd
    • Chong Kun Dang Pharmaceutical Corp
    • CJ HealthCare Corp
    • Daewoong Pharmaceutical Co Ltd
    • Eisai Co Ltd
    • Handa Pharmaceuticals LLC
    • Ilyang Pharmaceutical Co Ltd
    • Ironwood Pharmaceuticals Inc
    • Jeil Pharmaceutical Co Ltd
    • RaQualia Pharma Inc
    • Sam-A Pharm Co Ltd
    • Sun Pharma Advanced Research Company Ltd
    • Takeda Pharmaceutical Co Ltd
    • Yooyoung Pharm Co Ltd
    • Yuyu Pharma Inc
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Drug Profiles
    • (esomeprazole + sodium bicarbonate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • azeloprazole sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ceclazepide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-20043 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CJ-30065 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • colesevelam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexlansoprazole DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWP-14012 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • esomeprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-17DT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HND-009 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ilaprazole DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IYHCR-17 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JP-1366 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naronapride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • netazepide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pantoprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pantoprazole DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00000774 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SA-15001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tegoprazan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vonoprazan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • X-842 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YY-DXR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 08, 2018: Ironwood Pharmaceuticals presents IW-3718 data at the American College of Gastroenterology 2018 Annual Scientific Meeting
      • Jul 06, 2018: Ministry approves CJ Healthcares Gastro esophageal reflux treatment
      • Jul 06, 2018: RaQualia Announces Receipt of Milestone Payment from CJ HealthCare
      • Jun 21, 2018: Ironwood begins two Phase III trials of IW-3718
      • Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018
      • Jun 05, 2018: Ironwood Pharmaceuticals Presents IW-3718 Data Showing Improvements in Heartburn and Regurgitation Symptoms in Patients with Persistent GERD at Digestive Disease Week 2018
      • May 23, 2018: Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastro esophageal Reflux Disease (GERD) at Digestive Disease Week 2018
      • Apr 16, 2018: First clinical study successfully completed with X842, an innovative promising treatment for severe erosive GERD
      • Jul 20, 2017: Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastro esophageal Reflux Disease
      • Mar 09, 2017: Ironwood Pharmaceuticals provides update on key pipeline program IW-3718 at R&D Day 2017
      • Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride
      • Jul 11, 2016: Takeda Announces FDA Approval of Dexilant (dexlansoprazole) for Patients 12-17 Years of Age
      • Mar 23, 2016: Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastro esophageal Reflux Disease
      • Feb 18, 2016: RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea
      • Jan 27, 2016: FDA Approves Takeda's Dexilant SoluTab (dexlansoprazole)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Reflux Esophagitis (Gastro esophageal Reflux Disease), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by CJ HealthCare Corp, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Eisai Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Handa Pharmaceuticals LLC, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ilyang Pharmaceutical Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals Inc, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Sam-A Pharm Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Yooyoung Pharm Co Ltd, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Pipeline by Yuyu Pharma Inc, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products, H1 2019
  • Reflux Esophagitis (Gastro esophageal Reflux Disease) - Discontinued Products, H1 2019 (Contd..1), H1 2019

List of Figures

  • Number of Products under Development for Reflux Esophagitis (Gastro esophageal Reflux Disease), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Targets, H1 2019
  • Number of Products by Stage and Targets, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top